AXSM News and Press, Axsome Therapeutics Inc. From 04/21/23

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming 2023...

2023-04-20 09:45:00 ET After last year's tumble, the stock market is performing much better in 2023. That fits a historical pattern according to which downturns typically last only 10 months and rarely happen two years in a row. So investors can likely look forward to more decent performanc...

2023-04-20 06:20:00 ET Sometimes the experts get their growth stock predictions right, and sometimes they miss the mark. An average of Wall Street analyst forecasts suggests share prices of Axsome Therapeutics (NASDAQ: AXSM) could rise by 47% over the next 12 months. But so far this...

2023-04-19 17:54:02 ET Summary We maintain a buy rating on Axsome Therapeutics, Inc.: despite potential clinical/regulatory risks, Axsome's solid cash runway and Auvelity's initial launch progress support a positive outlook. The key catalysts in the near future include data from P...

2023-04-16 08:30:00 ET Investing in an up-and-coming growth stock can be a surefire way to generate some significant gains for your portfolio. One to consider now is Axsome Therapeutics (NASDAQ: AXSM) , a small biotech with big potential thanks to a couple of promising products. The...

2023-04-16 05:30:00 ET If you're looking to add some growth to your portfolio, you may find it in biotech stocks. Two in particular offer investors a terrific opportunity right now. That's because both of them are in the early stages of their growth story. And this means early investors cou...

NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Off...

NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarte...

2023-04-13 05:30:00 ET Today's tough market conditions mean many well-known stocks are trading for great prices. It's a good idea to pick them up now -- and benefit later. But it's also a good idea to explore some lesser-known names. Many of these companies are trading at interesting levels...

2023-04-12 08:35:00 ET Axsome Therapeutics ' (NASDAQ: AXSM) psychiatric drug Auvelity could reach blockbuster status by the end of the decade -- if the company can pull through its current cash crunch. It had just over $200 million in cash and cash equivalents on hand as of Dec. 31,...